What We're Reading: Page 2
Industry reads hand-picked by our editors
Jan 19, 2023
-
Axios
The struggle to contain the global threat of superbugs
-
The Wall Street Journal
Nursing Homes’ Use of Schizophrenia Drugs to Be Audited by U.S. Government
-
Evaluate Vantage
Biopharma’s stock market winners of 2022 revealed
Jan 18, 2023
Jan 17, 2023
-
The Wall Street Journal
A New U.S. Law Aims to Reduce Drug Prices. But First, It Might Raise Them.
-
FierceBiotech
NewAmsterdam’s Amgen castoff cuts LDL cholesterol in Phase 2
-
Bloomberg
Drugmakers Eli Lilly, AbbVie Leave UK Medicine-Pricing Agreement
-
The New York Times
The Father of the Abortion Pill
Jan 13, 2023
Jan 12, 2023
Jan 11, 2023
-
Bloomberg
Seagen’s New CEO David Epstein Hunts for Cancer Deals
-
C&EN
Agilent will double oligonucleotide capacity
-
CNN
FDA vaccine advisers ‘disappointed’ and ‘angry’ that early data about new Covid-19 booster shot wasn’t presented for review last year
-
MIT Technology Review
The scientist dreaming of a factory of unlimited human organs
Previous
